Gene Mack Positioned as the Chief Financial Officer at Imcyse

Gene Mack will contribute his profound understanding and skills of the financial sector to Imcyse as Chief Financial Officer, allowing the company to move forward with its groundbreaking solutions.

Fremont, CA: “I am excited to join Imcyse during this meaningful stage of scientific and corporate growth,” said Gene Mack. “The Company’s novel platform and clinical progress achieved to date uniquely positions Imcyse to deliver on near-term program milestones, and I look forward to working closely with Imcyses exceptionally talented and experienced team to bring revolutionary potential treatment options to patients.” Gene Mack has been named Chief Financial Officer at Imcyse.

Mr. Mack has more than 25 years of expertise in the life sciences industry, specialising in capital markets, business development, and corporate finance. Mr. Mack comes to Imcyse from OncoC4, a privately held biotechnology company that was formed when MSD acquired OncoImmune. He supervised OncoC4's financial establishment in addition to coordinating the successful transaction between the two companies.

 Mr. Mack has served as CFO for a number of biopharmaceutical firms in various stages of development and commercialization, raising approximately $150 million in IPO proceeds and other equity transactions in only the last three years. Mr. Mack provides a proven track record of success in the biotechnology industry, with over $600 million in M&A and licencing transactions to go along with his capital markets skills. Mr. Mack spent over fifteen years as a senior publishing analyst covering biotechnology and life sciences for a number of investment banks, including Gruntal & Co., Lazard, and HSBC, before switching to an operational CFO seven years ago. Gene graduated from Fordham University with a B.S. in Biochemistry and an MBA in Finance.

“We are thrilled to welcome Gene as our new CFO,” said Denis Bedoret, Ph.D., Chief Executive Officer of Imcyse. “Gene brings a deep knowledge and expertise of the financial sector, and I am confident that he will be an invaluable addition to our global executive management team as we work to pioneer the next generation of immunotherapeutics in autoimmune diseases.”